Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
CompletedNCT05198310
Kiniksa Pharmaceuticals, Ltd.Arthritis, Rheumatoid
Start: 2021-12-14End: 2024-05-06Updated: 2025-07-22